Hodgkin Lymphoma News and Research

RSS

Some cancers linked to extremely low frequency electromagnetic fields

The researchers opted to study this group, because railway workers in Switzerland tend to change jobs infrequently and are exposed to much higher levels of electromagnetic field radiation than the general population.

24 May 2007

FDA approves VELCADE plus DOXIL combination for multiple myeloma

Ortho Biotech Products has announced the U.S. Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in combination with VELCADE (bortezomib) for Injection to treat patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy.

23 May 2007

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma (malignancy involving lymphatic tissue) of 20 percent to 30 percent, and a three-fold increase in the risk of another type of lymphoma, according to a study in the May 9 issue of JAMA.

9 May 2007

Hepatitis C increases risk for non-Hodgkin's lymphoma

Researchers in the U.S. have found that an infection with the hepatitis C virus increases the risk of a person developing non-Hodgkin's lymphoma.

8 May 2007

Aspirin use linked to moderate drop in cancer risk

A new American Cancer Society study finds men and women who used adult-strength aspirin (325 mg or more) daily for five or more years had an approximately 15 percent lower rate of developing any cancer than those who did not use aspirin.

20 Apr 2007

Novel method to expand the number of immune system "natural killer" cells from blood cells outside the body

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body.

19 Apr 2007

Factors that dictate risk of developing primary or secondary cancer

Every day, people make assumptions, educated and not, about their risk for developing cancer.

18 Apr 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007

Predicting cancer risk in the long term

Every day, people make assumptions, educated and not, about their risk for developing cancer.

17 Apr 2007

New test identifies suitable lymphoma patients likely to respond to new therapy

Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients who'll be most likely to benefit from it.

20 Feb 2007

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Treatments for childhood cancer have resulted in a current overall cure rate of over 70 percent. However, long-term survivors of childhood cancer are at a higher risk of developing a secondary cancer than the general population.

20 Feb 2007

New drug to combat Gastrointestinal graft-vs.-host disease in stem-cell patients shows significant reduction in deaths

Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers.

23 Jan 2007

New guidelines for assessing lymphoma response to treatment

The guidelines will provide clinicians worldwide with uniform criteria to compare and interpret clinical trials of lymphoma treatments and should facilitate the development of new therapies.

23 Jan 2007

Cost-effectiveness of lipid screening in Hodgkin's disease survivors

Hodgkin's lymphoma survivors who have lipid screening every five years to detect high cholesterol will live a half year longer than patients who don't have the screening and the intervention is cost-effective, according to a study presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.

8 Nov 2006

Thyroid cancer among women in the U.S. has increased

The number of new cases of thyroid cancer among women in the U.S. has increased over the past decade despite a decline among women in mortality rates for most cancers, according to a report released Wednesday by the North American Association of Central Cancer Registries, the National Cancer Institute, CDC and the American Cancer Society, Long Island Newsday reports.

7 Sep 2006